High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. METHODS: We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DL(CO)). RESULTS: A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DL(CO): at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DL(CO) (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). CONCLUSIONS: Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DL(CO) in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“PANTHER-IPF, compared this three-drug combination (acetylcysteine, prednisone, and azathioprine) to acetylcysteine alone and placebo and found an increased rate of hospitalizations and death (P=0.01) in the triple therapy arm compared to placebo [62]. No physiological or clinical benefit was found in the triple therapy group”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, a recent trial with high doses of the antioxidant acetylcysteine appeared to attenuate the progression of IPF (25).”
From Adult-onset pulmonary fibrosis caused by mutations in telomerase (2007) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
The St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Idiopathic Pulmonary Fibrosis: Clinical Relevance of Pathologic Classification
KATZENSTEIN, A.-L. A., & MYERS, J. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.4.9707039 · Cited by 1,261
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039 · cited 1×
“Blood alkaline phosphatase increased 6 6 (8) 1 1 (1)”
BackgroundGross, T. J., & Hunninghake, G. W. (2001) · New England Journal of Medicine · doi:10.1056/nejmra003200 · Cited by 962
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Mechanisms of Pulmonary Fibrosis
Thannickal, V. J., Toews, G. B., White, E. S., Lynch III, J. P., & Martinez, F. J. (2004) · Annual Review of Medicine · doi:10.1146/annurev.med.55.091902.103810 · Cited by 808 · cited 3×
“Blood lactate dehydrogenase increased 6 6 (8) 2 2 (3)”
BackgroundChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764 · cited 1×
“Respiratory tract infection† 22 20 (25) 27 24 (32)”
Research works printed but not linked: 6
- 15. thione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994;7:431-6.
- 29. Quanjer PH. Standardized lung function testing: report of working party. Bull Eur Physiopathol Respir 1983;19:Suppl 5:195.
- 30. Standardized lung function testing: official statement of the European Respiratory Society. Eur Respir J Suppl 1993;16:1-100.
- 12. functional trends. Am J Respir Crit Care Med 2003;168:531-7.
- 37. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH guidelines: 'efficacy' topics. E6. Good clinical practice: consolidated guideline. (Accessed October 28, 2005, at http://www. ich.org/cache/compo/276-254-1.html.)
- 23. vival in idiopathic pulmonary fibrosis. Eur Respir J 2005;25:96-103.
Cited by
Items 301–400 of 960
Goodson, A. G., Cotter, M. A., Cassidy, P., Wade, M., Florell, S. R., Liu, T., Boucher, K. M., & Grossman, D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1890 · Cited by 46
“It is commercially available, inexpensive, Food and Drug Administration approved for acetaminophen toxicity (25), and more recently has been used to preserve lung function in patients with idiopathic pulmonary fibrosis (26) and to prevent contrast medium–induced nephropathy in patients undergoing angioplasty (27).”
BackgroundPirfenidone Initiates a New Era in the Treatment of Idiopathic Pulmonary Fibrosis
Selvaggio, A. S., & Noble, P. W. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-120214-013614 · Cited by 54
Corilagin Attenuates Aerosol Bleomycin-Induced Experimental Lung Injury
Wang, Z., Guo, Q., Zhang, X., Xiao, L., Li, W., Xi-tao, M., & Ma, L. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15069762 · Cited by 46
“These results were in line with previous studies, which showed the efficacy of ROS scavengers such as superoxide dismutase (SOD) and N-acetylcysteine in prevention of bleomycin-induced lung epithelial damage and fibrosis [15,16].”
ResultSmoking-Related Interstitial Lung Disease
Hagmeyer, L., & Randerath, W. J. (2015) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2015.0043 · Cited by 55
Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells
Park, J. S., Park, M.-Y., Cho, Y., Lee, J. H., Yoo, C., Lee, C., & Lee, S. M. (2016) · Inflammation · doi:10.1007/s10753-016-0393-4 · Cited by 47
Clinical review: Idiopathic pulmonary fibrosis—Past, present and future
Dempsey, O. J. (2006) · Respiratory Medicine · doi:10.1016/j.rmed.2006.08.017 · Cited by 62
The Diagnosis and Treatment of Pulmonary Fibrosis
Kreuter, M., Müller-Ladner, U., Costabel, U., Jonigk, D. D., & Heußel, C. P. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0018 · Cited by 57
Self-citationCu, A., Ye, Q., Sarrı́a, R., Nakamura, S., Guzman, J., & Costabel, U. (2009) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 43
Self-citationGuidelines for the Medical Treatment of Idiopathic Pulmonary Fibrosis
Xaubet, A., Molina‐Molina, M., Acosta, O., Bollo, E., Castillo, D., Fernández‐Fabrellas, E., Rodríguez-Portal, J. A., Valenzuela, C., & Ancochea, J. (2017) · Archivos de Bronconeumología · doi:10.1016/j.arbr.2017.03.001 · Cited by 49
Dyspnea in interstitial lung disease
Collard, H. R., & Pantilat, S. Z. (2008) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e3282ff6336 · Cited by 47
Current management strategies for systemic sclerosis.
Nihtyanova, S. I., Ong, V. H., & Denton, C. P. (2014) · PubMed · Cited by 49
The role of dimethylarginine dimethylaminohydrolase ( DDAH ) in pulmonary fibrosis
Janssen, W., Pullamsetti, S. S., Cooke, J. P., Weißmann, N., Günther, A., & SCHERMULY, R. T. (2012) · The Journal of Pathology · doi:10.1002/path.4127 · Cited by 49
Arafa, M. H., Mohamed, D. A.-E., & Atteia, H. H. (2013) · Environmental Toxicology · doi:10.1002/tox.21891 · Cited by 43
RetractedThe big clinical trials in idiopathic pulmonary fibrosis
Luppi, F., Spagnolo, P., Cerri, S., & Richeldi, L. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e3283567ff9 · Cited by 43
Dietary Supplementation with Pressurized Whey in Patients with Cystic Fibrosis
Lands, L. C., Iskandar, M. M., Beaudoin, N., Meehan, B., Dauletbaev, N., & Berthiuame, Y. (2010) · Journal of Medicinal Food · doi:10.1089/jmf.2008.0326 · Cited by 42
Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines
Чучалин, А. Г., Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Демура, Т. А., Ilkovich, M. M., Коган, Е. А., Samsonova, M. V., Speranskaya, A. A., Tyurin, I. E., et al. (2016) · PULMONOLOGIYA · doi:10.18093/0869-0189-2016-26-4-399-419 · Cited by 49
Glutathione revisited: a better scavenger than previously thought
Haenen, G. R. M. M., & Bast, A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00260 · Cited by 46
“In idiopathic pulmonary fibrosis patients three times 600 mg daily resulted in less worsening of the lung function (Demedts et al., 2005).”
BackgroundPatient-Reported Outcomes in Idiopathic Pulmonary Fibrosis Research
Swigris, J. J., & Fairclough, D. L. (2012) · CHEST Journal · doi:10.1378/chest.11-2602 · Cited by 46
Ando, K., Sekiya, M., Tobino, K., & Takahashi, K. (2013) · Lung · doi:10.1007/s00408-013-9513-1 · Cited by 41
Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis
Azuma, A. (2010) · Expert Review of Respiratory Medicine · doi:10.1586/ers.10.32 · Cited by 41
Clifford, R. E., Coleman, J. K. M., Balough, B. J., Liu, J., Kopke, R. D., & Jackson, R. L. (2011) · Otolaryngology · doi:10.1177/0194599811414496 · Cited by 48
Reactive oxygen species and synthetic antioxidants as angiogenesis modulators: Clinical implications
Radomska-Leśniewska, D. M., Hevelke, A., Skopiński, P., Bałan, B. J., Jóźwiak, J., Rokicki, D., Skopińska-Różewska, E., & Białoszewska, A. (2015) · Pharmacological Reports · doi:10.1016/j.pharep.2015.10.002 · Cited by 47
Lung involvement in inflammatory rheumatic diseases
Kelly, C. A., Iqbal, K., Iman-Gutierrez, L., Evans, P., & Manchegowda, K. A. (2016) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.10.004 · Cited by 43
Mishra, A., Bhattacharya, P., Paul, S., Paul, R., & Swarnakar, S. (2011) · Lung India · doi:10.4103/0970-2113.83972 · Cited by 43
“Several trials with different agents like colchicin,[3,4] INF-γ,[5-7] antioxidants,[8,9] pirfenidone,[10,11] and”
BackgroundManagement of Idiopathic Pulmonary Fibrosis in the Elderly Patient
Meyer, K. C., Danoff, S. K., LANCASTER, L. H., & Nathan, S. D. (2015) · CHEST Journal · doi:10.1378/chest.14-2475 · Cited by 46
Decramer, M., & Janssens, W. (2010) · European Respiratory Review · doi:10.1183/09059180.00003610 · Cited by 43
Reyes, D. R. A., Gomes, M. J., Rosa, C. M., Pagan, L. U., Damatto, F. C., Damatto, R. L., Deprá, I. C., de Campos, D. H. S., Fernandez, A. A. H., Martinez, P. F., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000486115 · Cited by 47
Ishikawa, N., Ohlmeier, S., Salmenkivi, K., Myllärniemi, M., Rahman, I., Mazur, W., & Kinnula, V. L. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-123 · Cited by 45
“Both IPF and COPD have been shown to be associated with oxidative/nitrosative stress [5-7].”
Current diagnosis and management of idiopathic pulmonary fibrosis: A survey of academic physicians
Collard, H. R., Loyd, J. E., King, T. E., & LANCASTER, L. H. (2007) · Respiratory Medicine · doi:10.1016/j.rmed.2007.03.012 · Cited by 42
“[15-21] Third, the increasingly accepted pathophysiologic paradigm of abnormal wound healing in which inflammation plays a limited role argues against the traditional approach to therapy (corticosteroids and cytotoxic agents) proposed by the consensus statement.”
BackgroundN-acetylcysteine as an anti-oxidant and anti-inflammatory drug and its some clinical applications
Radomska-Leśniewska, D. M., & Skopiński, P. (2012) · Cited by 54
Fen, F., Zhang, J., Wang, Z., Wu, Q., & Zhou, X. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7579 · Cited by 62
“The studies reporting on adverse effects were also divided into a high‐qu ality (13,14,16,19,20,31,33,38) and a low‐quality (18,27,36,37) subgroup, and no significant differences were observed between the two groups (Fig.”
BackgroundMethodInfluentialHagaman, J. T., Kinder, B. W., & Eckman, M. H. (2010) · Lung · doi:10.1007/s00408-009-9217-8 · Cited by 40
“Azathioprine, NAC, steroids 37% 31.6‐42.4% [ 6 ]”
BackgroundResultInfluentialMuramatsu, Y., Sugino, K., Ishida, F., Tatebe, J., Morita, T., & Homma, S. A. (2015) · Respiratory Investigation · doi:10.1016/j.resinv.2015.11.004 · Cited by 38
Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients
Huang, H. F., Dai, H. P., Kang, J., Chen, B. Y., Sun, T. Y., & Xu, Z. (2015) · Medicine · doi:10.1097/md.0000000000001600 · Cited by 41
p63 – Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis
Murata, K., Ota, S., Niki, T., Goto, A., Li, C.-P., Ruriko, U. M. R., Ishikawa, S., Aburatani, H., Kuriyama, T., & Fukayama, M. (2007) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.03.006 · Cited by 41
Vuorinen, K., Ohlmeier, S., Leppäranta, O., Salmenkivi, K., Myllärniemi, M., & Kinnula, V. L. (2008) · Journal of Histochemistry & Cytochemistry · doi:10.1369/jhc.2008.951806 · Cited by 40
“In addition, PDGFRa is induced by a variety of factors such as pollutants, asbestos fibers, and ROS (Gonzalez-Rubio et al. 1996; Bonner et al. 1998; Lasky et al. 1998; Bonner 2007).”
BackgroundInfluentialAntifibrosis: To Reverse the Irreversible
Paz, Z., & Shoenfeld, Y. (2009) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-009-8157-7 · Cited by 43
Update on diagnosis and treatment of idiopathic pulmonary fibrosis
Martínez, J. A. B., Baldi, B. G., da Costa, C. H., Jezler, S. F. D. O., Lima, M. S., & Rufino, R. (2015) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132015000000152 · Cited by 43
“(20) The methodological limitations of that study(20) led to a randomized clinical trial designated PANTHER-IPF, conducted by the Idiopathic Pulmonary Fibrosis Clinical Research Network, sponsored by the US National Heart, Lung, and Blood Institute, and comparing the effects of NAC alone with those of placebo in patie…”
MethodDeglycosylated bleomycin has the antitumor activity of bleomycin without pulmonary toxicity
Burgy, O., Wettstein, G., Bellaye, P., Décologne, N., Racoeur, C., Goirand, F., Beltramo, G., Hernandez, J., Kénani, A., Camus, P., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7785 · Cited by 44
Pharmacological management of IPF
Borie, R., Justet, A., Beltramo, G., Manali, E. D., Pradère, P., Spagnolo, P., & Crestani, B. (2016) · Respirology · doi:10.1111/resp.12778 · Cited by 42
Loveman, E., Copley, V. R., Colquitt, J. L., Scott, D. A., Clegg, A. J., Jones, J., O’Reilly, K. M., Singh, S., Bausewein, C., & Wells, A. U. (2015) · Health Technology Assessment · doi:10.3310/hta19200 · Cited by 41
“A cost–utility decision-analytic model was developed to compare the cost-effectiveness of pharmacological interventions for the treatment of IPF.”
MethodResultInfluentialXaubet, A., Ancochea, J., & Molina‐Molina, M. (2017) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2016.11.035 · Cited by 45
Lynch, J. P., Fishbein, M. C., Saggar, R., Zisman, D. A., & Belperio, J. A. (2007) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.1.3.377 · Cited by 37
“Any fool can make a rule and any fool will mind it”
Wells, A. U. (2016) · BMC Medicine · doi:10.1186/s12916-016-0562-1 · Cited by 38
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Kim, D. S. (2012) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2012.01.001 · Cited by 39
Aesif, S. W., Anathy, V., Havermans, M., Guala, A. S., Ckless, K., Taatjes, D. J., & Janssen-Heininger, Y. M. W. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080736 · Cited by 38
Experimental Therapies in Hypertrophic Cardiomyopathy
Marian, A. J. (2009) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-009-9132-7 · Cited by 36
“Likewise, the observed anti-fibrotic effect of NAC is in accord with the findings in other models and organs [12, 27, 32, 39, 40].”
Verma, G., Marras, T. K., Chowdhury, N., & Singer, L. G. (2011) · Canadian Respiratory Journal · doi:10.1155/2011/109635 · Cited by 41
“Recent clinical trials for IPF have included some evaluation of HRQL, although no therapies have shown a positive impact on HRQL (1-5).”
BackgroundMethodPharmacotherapy of systemic lupus erythematosus
Francis, L., & Perl, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902971003 · Cited by 35
The Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis
Behr, J. (2013) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2013.0875 · Cited by 44
Self-citationXaubet, A., Ancochea, J., & Molina‐Molina, M. (2016) · Medicina Clínica · doi:10.1016/j.medcli.2016.11.004 · Cited by 41
Efficacy of antioxidant in idiopathic pulmonary fibrosis: A systematic review and meta-analysis
Kandhare, A. D., Mukherjee-Kandhare, A. A., Ghosh, P., & Bodhankar, S. L. (2016) · EXCLI journal · doi:10.17179/excli2016-619 · Cited by 39
“Hence, pharmacological interventions acquired more attention as treatment strategies for IPF (Bando et al., 2010; Behr et al., 2009, 2016; Chan et al., 2013; Demedts et al., 2005; Homma et al., 2012; Jiang et al., 2012; Martinez et al., 2014; Taniguchi et al., 2010; Tomioka et al., 2005).”
BackgroundCrișan-Dabija, R. A., Pavel, C.-A., Popa, I. V., Țăruș, A., & Burlacu, A. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00387 · Cited by 39
Hong, X., Wang, L., Zhang, K., Liu, J., & Liu, J. (2022) · Cells · doi:10.3390/cells11050877 · Cited by 38
Clinical use of biomarkers of survival in pulmonary fibrosis
Thomeer, M., Grutters, J. C., Wuyts, W. A., Willems, S., & Demedts, M. (2010) · Respiratory Research · doi:10.1186/1465-9921-11-89 · Cited by 38
“The spinoff of the IFIGENIA trial aimed to quantify the risk for mortality in 155 IPF patients after 4 years of the date of inclusion in the IFIGENIA study [33].”
MethodSelf-citationLymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis
Glasgow, C. G., El‐Chemaly, S., & Moss, J. (2012) · European Respiratory Review · doi:10.1183/09059180.00009311 · Cited by 37
Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis
Thong, L., McElduff, E. J., & Henry, M. T. (2023) · Life · doi:10.3390/life13020486 · Cited by 37
“The authors concluded that the addition of NAC to the standard therapy of prednisolone and azathioprine had better preserved vital capacity and DLCO [105].”
BackgroundType D or 'distressed' personality in sarcoidosis and idiopathic pulmonary fibrosis.
Elfferich, M., Vries, J. D., & Drent, M. (2011) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 43
Evidence-based treatment strategies in idiopathic pulmonary fibrosis
Behr, J. (2013) · European Respiratory Review · doi:10.1183/09059180.00001013 · Cited by 40
Self-citationTreatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group
Sköld, C. M., Bendstrup, E. M., Myllärniemi, M., Guðmundsson, G., Sjåheim, T., Hilberg, O., Altraja, A., Kaarteenaho, R. L., & Ferrara, G. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12571 · Cited by 38
Abbasifard, M., Khorramdelazad, H., Rostamian, A., Rezaeian, M., Saeed-Askari, P., Sharifi, G. T. K., Kardoust, M., Sharifi, M. T. K., & Najafizadeh, S. R. (2023) · Trials · doi:10.1186/s13063-023-07083-9 · Cited by 35
“Accordingly, anti-oxidant therapy plays an essential role in limiting the toxicity of immunosuppressant treatments [21].”
BackgroundRelationship Between Redox Status and Cell Fate in Immunity and Autoimmunity
Ortona, E., Maselli, A., Delunardo, F., Colasanti, T., Giovannetti, A., & Pierdominici, M. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5752 · Cited by 35
Regulation of apoptosis through cysteine oxidation: implications for fibrotic lung disease
Janssen-Heininger, Y. M. W., Aesif, S. W., van der Velden, J. L. J., Guala, A. S., Reiss, J. N., Roberson, E. C., Budd, R. C., Reynaert, N. L., & Anathy, V. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05553.x · Cited by 33
Analysis of Carbonylated Proteins in Bronchoalveolar Lavage of Patients with Diffuse Lung Diseases
Bargagli, E., Penza, F., Vagaggini, C., Magi, B., Perari, M. G., & Rottoli, P. (2007) · Lung · doi:10.1007/s00408-007-9001-6 · Cited by 33
“serves vital capacity and diffusing capacity for carbonmonoxide better than standard therapy alone [26].”
BackgroundHoo, Z. H., & Whyte, M. K. B. (2011) · Thorax · doi:10.1136/thoraxjnl-2011-200515 · Cited by 38
“gov/ NCT00650091), following previous evidence of beneficial effects in the IFIGENIA trial.(46) The last paper in this section, from Knobloch et al,(47) pertains to the roles of ASMCs and inflammation in the pathogenesis of IPF.”
Maarman, G. J. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63245-2_10 · Cited by 36
Shi, H., Yin, D., Bonella, F., Kreuter, M., Oltmanns, U., Li, X., Peng, S., & Wei, L. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1121-2 · Cited by 34
“The randomized placebo-controlled trial IFIGENIA investigated NAC treatment vs the standard treatment with prednisone plus azathioprine in 182 mild to moderate IPF patients over 48 weeks [24].”
BackgroundMethodFeng, H., Moriyama, T., Ohuchida, K., Sheng, N., Iwamoto, C., Shindo, K., Shirahane, K., Ikenaga, N., Nagai, S., Nakata, K., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01939-1 · Cited by 36
IPF: New insight in diagnosis and prognosis
Caminati, A., & Harari, S. A. (2010) · Respiratory Medicine · doi:10.1016/j.rmed.2010.03.012 · Cited by 37
Rodríguez, L. R., Bui, S., Beuschel, R. T., Ellis, E., Liberti, E., Chhina, M., Cannon, B., Lemma, M., Nathan, S. D., & Grant, G. (2019) · Molecular Medicine · doi:10.1186/s10020-019-0096-z · Cited by 32
Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis
Avdeev, S. N., Айсанов, З. Р., Belevskiy, А. S., Ilkovich, M. M., Коган, Е. А., Мержоева, З. М., Petrov, D., Samsonova, M. V., Terpigorev, S. A., Трушенко, Н. В., et al. (2022) · PULMONOLOGIYA · doi:10.18093/0869-0189-2022-32-3-473-495 · Cited by 32
Synthetic and semi-synthetic antioxidants in medicine and food industry: a review
Tauchen, J., Huml, L., Jurášek, M., Regenstein, J. M., & Özoğul, F. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1599816 · Cited by 39
Pharmacological treatment of idiopathic pulmonary fibrosis: an update
Spagnolo, P., Wells, A. U., & Collard, H. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.01.001 · Cited by 33
Zolak, J. S., & de Andrade, J. A. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.006 · Cited by 40
“The Study of the Effects of High-Dose N-Acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IFIGENIA) compared the effectiveness of 1-year combined antiinflammatory therapy of azathioprine and prednisone with or without the antioxidant NAC.(47) At the end of 1 year, patients randomized to the triple therapy arm had…”
Clinical Predictors of Survival in Idiopathic Pulmonary Fibrosis
Kim, J. H., Lee, J. H., Ryu, Y. J., & Chang, J. H. (2012) · Tuberculosis & respiratory diseases · doi:10.4046/trd.2012.73.3.162 · Cited by 33
Wang, W., Li, D., Ding, X., Zhao, Q., Chen, J., Tian, K., Qiu, Y., & Lu, L. (2017) · Toxicology Letters · doi:10.1016/j.toxlet.2017.07.903 · Cited by 32
Seeing cilia: imaging modalities for ciliary motion and clinical connections
Lever, J. E. P., Shei, R., Bermingham, B., Phillips, S. E., Turner, B., Rowe, S. M., & Solomon, G. M. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00556.2017 · Cited by 33
“These results should be interpreted cautiously, given that combination therapy studied in the PANTHER-IPF trial (prednisone, azathioprine, and acetylcysteine or acetylcysteine alone) was inconclusive (28, 56).”
ResultWells, A. U., Behr, J., & Silver, R. M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken311 · Cited by 36
“(ii) Pulmonary function trends are usually analysed as percentage changes from baseline values (rather than percentage changes of normal predicted values), although the IFIGENIA study of anti-oxidant therapy in IPF was an important exception, in that absolute changes of VC and DLCO were used to define the primary end-…”
BackgroundMethodSelf-citationZhang, Q., Li, J., Li, Y., Che, H., Chen, Y., Dong, J., Xian, C. J., Miao, D., Wang, L., & Ren, Y. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15528 · Cited by 31
Pathological networking: a new approach to understanding COPD
Sabroe, I., Parker, L. C., CALVERLEY, P. M. A., Dower, S., & Whyte, M. K. B. (2007) · Postgraduate Medical Journal · doi:10.1136/thx.2007.077768 · Cited by 30
Idiopathic pulmonary fibrosis mortality: update on trends in the modern treatment era
Podolanczuk, A. J., & Raghu, G. (2024) · European Respiratory Journal · doi:10.1183/13993003.01305-2024 · Cited by 31
Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis?
Clarke, D. L., Murray, L. A., Crestani, B., & Sleeman, M. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.010 · Cited by 33
Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future
Staitieh, B. S., Renzoni, E. A., & Veeraraghavan, S. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.991751 · Cited by 32
Proteome Analysis of Bronchoalveolar Lavage Fluid in Chronic Hypersensitivity Pneumonitis
Okamoto, T., Miyazaki, Y., Shirahama, R., Tamaoka, M., & Inase, N. (2012) · Allergology International · doi:10.2332/allergolint.11-oa-0315 · Cited by 29
Parnell, S. E., Sulik, K. K., Dehart, D. B., & Chen, S.-Y. (2010) · Alcohol · doi:10.1016/j.alcohol.2010.05.006 · Cited by 29
“Its utility is also being explored for the treatment of cancer, cardiovascular disease, human immunodeficiency virus infection, nephrotoxicity resulting from imaging contrast agents, chronic obstructive pulmonary disease, and pulmonary fibrosis (Decramer et al., 2005; Demedts et al., 2005; Marenzi et al., 2006).”
BackgroundInvestigational approaches to therapies for idiopathic pulmonary fibrosis
Gomer, R. H., & Lupher, M. L. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.484018 · Cited by 29
“DLCO also deteriorated less in those given NAC (relative difference: 24%, p = 0.003).”
BackgroundInfluentialPirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program
Richeldi, L., & du Bois, R. M. (2011) · Expert Review of Respiratory Medicine · doi:10.1586/ers.11.52 · Cited by 31
Review: New perspectives in the treatment of idiopathic pulmonary fibrosis
Rogliani, P., Mura, M., Porretta, M. A., & Saltini, C. (2008) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465808089363 · Cited by 34
“75 mmol per minute per kilopascal) compared to placebo [Demedts et al. 2005].”
BackgroundInfluentialUpdate on diffuse parenchymal lung disease
Harari, S. A., & Caminati, A. (2010) · European Respiratory Review · doi:10.1183/09059180.00002510 · Cited by 31
Dysregulation of very long chain acyl-CoA dehydrogenase coupled with lipid peroxidation
Kabuyama, Y., Suzuki, T., Nakazawa, N., Yamaki, J., Homma, Y., & Homma, Y. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00231.2009 · Cited by 28
“The data suggest that NAC has beneficial effects for patients with IPF (6).”
BackgroundIdiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age
Shaw, J., Marshall, T., Morris, H. G., Hayton, C., & Chaudhuri, N. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.111 · Cited by 34
“Triple therapy with prednisolone, azathioprine and N-acetylcysteine (NAC) became the treatment of choice following the publication of the IFIGENIA study that suggested this combination slowed the decline in lung function (6).”
BackgroundInterferon-γ1bfor the treatment of idiopathic pulmonary fibrosis
Bouros, D. E., Antoniou, K. M., Τzouvelekis, Α., & Siafakas, N. M. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.10.1051 · Cited by 30
Pirfenidone treatment of idiopathic pulmonary fibrosis
Gomer, R. H., Gan, & Herzog, E. L. (2011) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s12209 · Cited by 33
Treatments in idiopathic pulmonary fibrosis: time for a more targeted approach?
Mahendran, S., & Sethi, T. (2012) · QJM · doi:10.1093/qjmed/hcs076 · Cited by 33
“The IFIGENIA trial, a doubleblinded, randomized, controlled multi-centre trial, showed that the addition of NAC, added to prednisolone and azathiaprine, could attenuate the decline in forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) compared with patients on prednisolone and azathiaprine a…”
Effects of edaravone, a free-radical scavenger, on bleomycin-induced lung injury in mice
Tajima, S., Bando, M., Ishii, Y., Hosono, T., Yamasawa, H., Ohno, S., Takada, T., Suzuki, E., Gejyo, F., & Sugiyama, Y. (2008) · European Respiratory Journal · doi:10.1183/09031936.00164407 · Cited by 28
Piotrowski, W. J., Bestry, I., Białas, A. J., Boros, P. W., Grzanka, P., Jassem, E., Jastrzębski, D., Klimczak, D., Langfort, R., Lewandowska, K. B., et al. (2020) · Advances in respiratory medicine · doi:10.5603/arm.2020.0081 · Cited by 32
Kabuyama, Y., Oshima, K., Kitamura, T., Homma, Y., Yamaki, J., Munakata, M., & Homma, Y. (2007) · Genes to Cells · doi:10.1111/j.1365-2443.2007.01127.x · Cited by 28
Promising pharmacologic innovations in treating pulmonary fibrosis
Bhatt, N., Baran, C., ALLEN, J., MAGRO, C. M. J., & Marsh, C. B. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.03.003 · Cited by 29
Idiopathic Pulmonary Fibrosis: Recent Trials and Current Drug Therapy
Jones, M. G., Fletcher, S., & Richeldi, L. (2013) · Respiration · doi:10.1159/000356958 · Cited by 28
Clinical significance of serum hyaluronan in chronic fibrotic interstitial pneumonia
Inokoshi, Y., Tanino, Y., Wang, X., Sato, S., Fukuhara, N., Nikaido, T., Fukuhara, A., Saito, J., Frevert, C. W., & Munakata, M. (2013) · Respirology · doi:10.1111/resp.12144 · Cited by 28
Metadata
- Authors
- Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., Nicholson, A. G., Verbeken, E. K., Verschakelen, J., Flower, C. D. R., Capron, F., Petruzzelli, S., De Vuyst, P., van den Bosch, J. M. M., Rodriguez-Becerra, E., Corvasce, G., Lankhorst, I., Sardina, M., & Montanari, M.
- Affiliations
- KU Leuven (BE)
- LMU Klinikum (DE)
- Johannes Gutenberg University Mainz (DE)
- Ruhrlandklinik (DE)
- Amsterdam UMC Location University of Amsterdam (NL)
- University of Edinburgh (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Royal Brompton Hospital (GB)
- Hôpital Antoine-Béclère (FR)
- University of Pisa (IT)
- Zambon (Italy) (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-24
- Volume
- 353
- Issue
- 21
- Pages
- 2229-2242
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125322938
- Cited by
- 964
- References
- 48
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 33 · 2023: 32 · 2022: 17 · 2021: 29 · 2020: 28 · 2019: 26 · 2018: 24 · 2017: 31 · 2016: 49 · 2015: 64 · 2014: 63 · 2013: 72 · 2012: 79
- FWCI
- 48.21
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Document Server@UHasselt (UHasselt) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- idiopathic pulmonary fibrosis, N-acetylcysteine, usual interstitial pneumonia, prednisone, azathioprine, vital capacity, diffusing capacity for carbon monoxide, lung function decline, mortality, myelosuppression, antioxidant therapy, disease-modifying therapy, treatment efficacy and safety, adverse events
- MeSH terms
- Acetylcysteine, Aged, Anti-Inflammatory Agents, Antioxidants, Azathioprine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Prednisone, Pulmonary Diffusing Capacity, Pulmonary Fibrosis, Vital Capacity, Exercise Tolerance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.